Developer of drugs research platform intended to offer treatment of amyloidosis and amyloid-related diseases. The company's platform designs and develops new treatments for systemic amyloidosis and amyloid-related diseases, Alzheimer's disease and type II diabetes and targeting the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases, enabling doctors to cure amyloid-related diseases and to speed up patients' access to new medicines.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Grant | 29-Sep-2008 | $7M | Completed | Generating Revenue | ||
1. Early Stage VC | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Mark Pepys Ph.D | Founder, Head of Medicine & Director |
Name | Representing | Role | Since |
---|---|---|---|
Cengiz Tarhan | UCL Business | Director | 000 0000 |
Mark Pepys Ph.D | Pentraxin Therapeutics | Founder, Head of Medicine & Director | 000 0000 |
Philip Hawkins Ph.D | Pentraxin Therapeutics | Director | 000 0000 |
Stephen Wood | Pentraxin Therapeutics | Director | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Wellcome Trust | Limited Partner | 000 0000 | 000000 0 | ||
Philip Hawkins | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Stephen Wood | Angel (individual) | Minority | 000 0000 | 000000 0 | |
UCL Business | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 |